1
by McDonagh, Marian S.
Published 2007
Oregon Health & Science University
...The combination of 2 drug entities in one dosage form is known as a fixed-dose combination product...

2
by McDonagh, Marian S.
Published 2007
Oregon Health & Science University
...The combination of 2 drug entities in one dosage form is known as a fixed-dose combination product...

3
by Smith, M. E. Beth
Published 2009
Oregon Health & Science University
...HMG-CoA reductase inhibitors (statins) and fixed-dose combination products containing a statin...

4
by Smith, M. E. Beth
Published 2009
Oregon Health & Science University
...HMG-CoA reductase inhibitors (statins) and fixed-dose combination products containing a statin...

5
by Smith, Beth Paterson
Published 2010
Oregon Health & Science University
... multiple sclerosis. Evidence suggested that all 3 interferon beta-1 products and glatiramer reduced...

6
by Smith, Beth Paterson
Published 2010
Oregon Health & Science University
... multiple sclerosis. Evidence suggested that all 3 interferon beta-1 products and glatiramer reduced...

7
by McDonagh, Marian S.
Published 2011
Oregon Health & Science University
... were highest with amphetamine-based products but similar among methylphenidate products. Evidence...

8
by McDonagh, Marian S.
Published 2011
Oregon Health & Science University
... were highest with amphetamine-based products but similar among methylphenidate products. Evidence...

9
by Lee, Nancy J.
Published 2008
Oregon Health & Science University
... Administration, causing a black box warning to be placed in each product's labeling. Several pharmacokinetic...

10
by Lee, Nancy J.
Published 2008
Oregon Health & Science University
... Administration, causing a black box warning to be placed in each product's labeling. Several pharmacokinetic...

11
by Jonas, Dan
Published 2008
Oregon Health & Science University
...-IgE medications, and combination products. The purpose of this review is to compare the benefits...

12
by Jonas, Dan
Published 2008
Oregon Health & Science University
...-IgE medications, and combination products. The purpose of this review is to compare the benefits...

13
by Jonas, Dan
Published 2011
Oregon Health & Science University

14
by Jonas, Dan
Published 2011
Oregon Health & Science University

15
by Jonas, Dan
Published 2011
Oregon Health & Science University

16
by Jonas, Dan
Published 2011
Oregon Health & Science University

17
by McDonagh, Marian S.
Published 2010
Oregon Health & Science University

18
by McDonagh, Marian S.
Published 2010
Oregon Health & Science University

19
by Norris, Susan L., Weinstein, Jessica, Peterson, Kim, Thakurta, Sujata
Published 2010
Oregon Health & Science University
..., and kidneys that leads to the production of biologically active agents, including angiotensin I and II...

20
by Norris, Susan L., Weinstein, Jessica, Peterson, Kim, Thakurta, Sujata
Published 2010
Oregon Health & Science University
..., and kidneys that leads to the production of biologically active agents, including angiotensin I and II...